Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
Aduro Biotech announced that the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase I clinical trial of its anti-CD27 antibody.
Read more
Brigitte Drees nieuwe directeur Pivot Park
Brigitte Drees volgt Mirjam Mol-Arts op, welke 1 januari afscheid nam van het Pivot Park.
Read more
RA2day: addressing today’s regulatory topics
Zwiers Regulatory Consultancy is organising RA2day on April 13th 2018.
Read more
Over 50 companies based at Pivot Park!
Recently the number of companies based at Pivot Park reached the milestone of 50!
Read more
New at Pivot Park – PharmaCytics
PharmaCytics offers a drug delivery solution, based on an advanced prodrug approach.
Read more
InnatOss and MediSapiens Receive EU Grant to Personalize Lyme Diagnostics
Recently the number of companies based at Pivot Park reached the milestone of 50!
Read more
New at Pivot Park – Sterk Schakelen
Sterk Schakelen is now a member of the Pivot Park Community.
Read more
New at Pivot Park – CheckMark Labrecruitment
Since December 1st Checkmark Labrecruitment is present at Pivot Park.
Read more
ImmunoPrecise to Acquire ModiQuest Research BV
IMMUNOPRECISE ANTIBODIES LTD. announces that it has signed a binding letter of intent with ModiQuest Research BV.
Read more